echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The kl-A289 injection, an innovative drug in Collum Pharmaceuticals, was approved clinically.

    The kl-A289 injection, an innovative drug in Collum Pharmaceuticals, was approved clinically.

    • Last Update: 2020-08-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: KL-A289 injections are intended for the treatment of advanced solid tumors. on August 4,
    , Collum Pharmaceuticals announced that KL-A289 injections of the innovative tumor immunology drug COlumbotai BiopharmaceuticalCoB.e., a controlling subsidiary of the Company, and Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd., had been approved by the State Drug Administration for clinical trials.
    KL-A289 injection is a new generation of tumor immunocheckpoint inhibitors jointly developed by Colleen Pharmaceuticals and Anyuan Pharmaceuticals with independent intellectual property rights, the mechanism of action is relatively clear, which can lift the inhibition of anti-tumor T cells, enhance the body's immune response to tumors, and is intended to be used in the treatment of advanced solid tumors.
    preclinical studies show that KL-A289 injections show anti-tumor activity in single drugs in tumor animal models, and have the potential of combination with other immunocheckpoint inhibitors, chemotherapy drugs, etc., and have good pharmacokinetic characteristics, both good safety and tolerance.
    , after inquiry, there is no global target drug approved for market.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.